Annual Cash & Cash Equivalents
$13.85 M
-$4.36 M-23.92%
December 31, 2023
Summary
- As of March 6, 2025, OPRX annual cash & cash equivalents is $13.85 million, with the most recent change of -$4.36 million (-23.92%) on December 31, 2023.
- During the last 3 years, OPRX annual cash & cash equivalents has risen by +$3.34 million (+31.72%).
- OPRX annual cash & cash equivalents is now -83.64% below its all-time high of $84.68 million, reached on December 31, 2021.
Performance
OPRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$16.13 M
+$1.17 M+7.80%
September 30, 2024
Summary
- As of March 6, 2025, OPRX quarterly cash and cash equivalents is $16.13 million, with the most recent change of +$1.17 million (+7.80%) on September 30, 2024.
- Over the past year, OPRX quarterly cash and cash equivalents has increased by +$6.20 million (+62.54%).
- OPRX quarterly cash and cash equivalents is now -81.87% below its all-time high of $88.95 million, reached on March 31, 2022.
Performance
OPRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
OPRX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -23.9% | +62.5% |
| 3 y3 years | +31.7% | -81.0% |
| 5 y5 years | +55.4% | -14.5% |
OPRX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -83.6% | at low | -81.9% | +64.4% |
| 5 y | 5-year | -83.6% | +31.7% | -81.9% | +64.4% |
| alltime | all time | -83.6% | >+9999.0% | -81.9% | +6092.8% |
OptimizeRx Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $16.13 M(+7.8%) |
| Jun 2024 | - | $14.96 M(-1.4%) |
| Mar 2024 | - | $15.18 M(+9.6%) |
| Dec 2023 | $13.85 M(-23.9%) | $13.85 M(+39.6%) |
| Sep 2023 | - | $9.92 M(+1.2%) |
| Jun 2023 | - | $9.81 M(-40.4%) |
| Mar 2023 | - | $16.44 M(-9.7%) |
| Dec 2022 | $18.21 M(-78.5%) | $18.21 M(-55.9%) |
| Sep 2022 | - | $41.33 M(-52.7%) |
| Jun 2022 | - | $87.39 M(-1.8%) |
| Mar 2022 | - | $88.95 M(+5.0%) |
| Dec 2021 | $84.68 M(+705.2%) | $84.68 M(-0.4%) |
| Sep 2021 | - | $85.06 M(+1.4%) |
| Jun 2021 | - | $83.92 M(+2.0%) |
| Mar 2021 | - | $82.28 M(+682.4%) |
| Dec 2020 | $10.52 M(-44.2%) | $10.52 M(-12.6%) |
| Sep 2020 | - | $12.03 M(-14.7%) |
| Jun 2020 | - | $14.11 M(-7.2%) |
| Mar 2020 | - | $15.21 M(-19.3%) |
| Dec 2019 | $18.85 M(+111.5%) | $18.85 M(-36.7%) |
| Sep 2019 | - | $29.76 M(-2.5%) |
| Jun 2019 | - | $30.54 M(+201.3%) |
| Mar 2019 | - | $10.13 M(+13.7%) |
| Dec 2018 | $8.91 M(+74.0%) | $8.91 M(-34.1%) |
| Sep 2018 | - | $13.52 M(+12.7%) |
| Jun 2018 | - | $12.00 M(+179.3%) |
| Mar 2018 | - | $4.30 M(-16.1%) |
| Dec 2017 | $5.12 M(-27.2%) | $5.12 M(+2.2%) |
| Sep 2017 | - | $5.01 M(-14.2%) |
| Jun 2017 | - | $5.84 M(-13.1%) |
| Mar 2017 | - | $6.72 M(-4.5%) |
| Dec 2016 | $7.03 M | $7.03 M(-7.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $7.57 M(+0.1%) |
| Jun 2016 | - | $7.57 M(+0.2%) |
| Mar 2016 | - | $7.55 M(-8.0%) |
| Dec 2015 | $8.21 M(+138.1%) | $8.21 M(+0.4%) |
| Sep 2015 | - | $8.17 M(+124.2%) |
| Jun 2015 | - | $3.65 M(+3.8%) |
| Mar 2015 | - | $3.51 M(+1.9%) |
| Dec 2014 | $3.45 M(+208.3%) | $3.45 M(+5.7%) |
| Sep 2014 | - | $3.26 M(-8.2%) |
| Jun 2014 | - | $3.55 M(-11.9%) |
| Mar 2014 | - | $4.03 M(+260.5%) |
| Dec 2013 | $1.12 M(+293.3%) | $1.12 M(+129.8%) |
| Sep 2013 | - | $486.70 K(+38.1%) |
| Jun 2013 | - | $352.40 K(+35.3%) |
| Mar 2013 | - | $260.40 K(-8.4%) |
| Dec 2012 | $284.30 K(-70.4%) | $284.30 K(+0.6%) |
| Sep 2012 | - | $282.60 K(-46.4%) |
| Jun 2012 | - | $527.50 K(-33.9%) |
| Mar 2012 | - | $797.50 K(-16.9%) |
| Dec 2011 | $959.20 K(-25.0%) | $959.20 K(-5.9%) |
| Sep 2011 | - | $1.02 M(+5.1%) |
| Jun 2011 | - | $969.80 K(-15.6%) |
| Mar 2011 | - | $1.15 M(-10.1%) |
| Dec 2010 | $1.28 M(+94.7%) | $1.28 M(+89.5%) |
| Sep 2010 | - | $674.40 K(-40.5%) |
| Jun 2010 | - | $1.13 M(+205.0%) |
| Mar 2010 | - | $371.40 K(-43.4%) |
| Dec 2009 | $656.40 K(-73.8%) | $656.40 K(-34.8%) |
| Sep 2009 | - | $1.01 M(-24.8%) |
| Jun 2009 | - | $1.34 M(-26.6%) |
| Mar 2009 | - | $1.82 M(-27.2%) |
| Dec 2008 | $2.50 M(+1748.4%) | $2.50 M |
| Dec 2007 | $135.40 K | - |
FAQ
- What is OptimizeRx annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for OptimizeRx?
- What is OptimizeRx annual cash & cash equivalents year-on-year change?
- What is OptimizeRx quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for OptimizeRx?
- What is OptimizeRx quarterly cash and cash equivalents year-on-year change?
What is OptimizeRx annual cash & cash equivalents?
The current annual cash & cash equivalents of OPRX is $13.85 M
What is the all time high annual cash & cash equivalents for OptimizeRx?
OptimizeRx all-time high annual cash & cash equivalents is $84.68 M
What is OptimizeRx annual cash & cash equivalents year-on-year change?
Over the past year, OPRX annual cash & cash equivalents has changed by -$4.36 M (-23.92%)
What is OptimizeRx quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of OPRX is $16.13 M
What is the all time high quarterly cash and cash equivalents for OptimizeRx?
OptimizeRx all-time high quarterly cash and cash equivalents is $88.95 M
What is OptimizeRx quarterly cash and cash equivalents year-on-year change?
Over the past year, OPRX quarterly cash and cash equivalents has changed by +$6.20 M (+62.54%)